Advertisement
Table 2 Hazard ratios for bDMARD-free remission failure (univariate analysis)
| Factor | HR (95% CI) | p value |
|---|---|---|
| Type of bDMARD | ||
| TNFi(mAb)/TNFi(R/P) | 0.56 (0.35–0.87) | 0.01 |
| TNFi(mAb)/CTLA4-Ig | 0.87 (0.48–1.57) | 0.65 |
| TNFi(mAb)/IL-6Ri | 0.42 (0.28–0.63) | < 0.01 |
| CTLA4-Ig/TNFi(R/P) | 0.64 (0.33–1.24) | 0.19 |
| CTLA4-Ig/IL-6Ri | 0.48 (0.25–0.91) | 0.03 |
| TNFi(R/P)/IL-6Ri | 0.75 (0.46–1.25) | 0.27 |
| Age (years) | 1.00 (0.99–1.01) | 0.88 |
| Sex, female/male | 0.79 (0.53–1.20) | 0.26 |
| Disease duration, < 2 years/≥ 2 years | 0.63 (0.45–0.88) | 0.01 |
| Disease duration (years) | 1.03 (1.01–1.05) | < 0.01 |
| Smoking status, current/previous or never | 0.62 (0.27–1.21) | 0.17 |
| Anti-CCP antibody, positive/negative | 1.47 (0.84–2.81) | 0.19 |
| Rheumatoid factor, positive/negative | 1.39 (0.91–2.21) | 0.13 |
| bDMARD-naïve, naïve/switch | 0.56 (0.40–0.79) | < 0.01 |
| Reason for discontinuation, remission/other reason | 0.36 (0.22–0.58) | < 0.01 |
| Boolean remission at the time of discontinuation, achieved/not achieved | 0.42 (0.29–0.60) | < 0.01 |
| Remission maintenance period before discontinuation, > 6 months/≥ 6 months | 0.33 (0.22–0.50) | < 0.01 |
| Methotrexate usage at the time of discontinuation, yes/no | 0.65 (0.45–0.96) | 0.03 |
| Methotrexate dosage at the time of discontinuation (mg/week) | 0.95 (0.92–0.99) | 0.02 |
| Glucocorticoid usage at the time of discontinuation, yes/no | 2.03 (1.46–2.82) | < 0.01 |
| Glucocorticoid dosage at the time of discontinuation (mg/day) | 1.01 (0.98–1.02) | 0.56 |
